Peregrine Capital Management LLC Immunovant, Inc. Transaction History

Peregrine Capital Management LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 02, 2021	SELL	$7.01 - $11.37 $2.04 Million - $3.31 Million	-291,456 Closed	0 $0
Q2 2021 Aug 03, 2021	SELL	$9.4 - $16.85 $146,141 - $261,966	-15,547 Reduced 5.06%	291,456 $3.08 Million
Q1 2021 May 11, 2021	BUY	$13.08 - $49.6 $1.86 Million - $7.06 Million	142,386 Added 86.5%	307,003 $4.92 Million
Q4 2020 Jan 19, 2021	SELL	$36.36 - $52.71 $547,145 - $793,180	-15,048 Reduced 8.38%	164,617 $7.6 Million
Q3 2020 Oct 20, 2020	BUY	$22.61 - $38.9 $4.06 Million - $6.99 Million	179,665 New	179,665 $6.32 Million

211

66.9M

2.3M

631K

Ticker IMVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 129,077,000
Market Cap $3.55B
Description
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of mya...

Get notified when there are updates to the investment portfolio of Peregrine Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Peregrine Capital Management LLC with notifications on news.